Edition:
United States

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

9.80USD
4:00pm EDT
Change (% chg)

$-0.01 (-0.10%)
Prev Close
$9.81
Open
$9.84
Day's High
$9.93
Day's Low
$9.75
Volume
14,747
Avg. Vol
40,689
52-wk High
$17.54
52-wk Low
$7.45

Latest Key Developments (Source: Significant Developments)

Corvus Pharma Announces Pricing Of Public Offering Of Common Stock
Thursday, 8 Mar 2018 09:04am EST 

March 8 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.06 MILLION COMMON SHARES PRICED AT $8.50PER SHARE.SAYS PUBLIC OFFERING OF 7.06 MILLION COMMON SHARES PRICED AT $8.50PER SHARE.  Full Article

Corvus Pharma Announces Proposed Public Offering Of Common Stock
Wednesday, 7 Mar 2018 04:05pm EST 

March 7 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CORVUS PHARMACEUTICALS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF UP TO $50.0 MILLION SHARES OF ITS COMMON STOCK​.  Full Article

Corvus Pharmaceuticals Qtrly Net Loss Per Share $0.58
Thursday, 1 Mar 2018 04:10pm EST 

March 1 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.58.Q4 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.  Full Article

Corvus Pharmaceuticals reports third quarter 2017 financial results
Thursday, 2 Nov 2017 04:10pm EDT 

Nov 2 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update.Net loss for three months ended September 30, 2017, was $12.7 million compared to $10.3 million for same period in 2016​.  Full Article

Corvus Pharmaceuticals qtrly ‍net loss per share $0.73​
Thursday, 3 Aug 2017 04:10pm EDT 

Aug 3 (Reuters) - Corvus Pharmaceuticals Inc :Corvus Pharmaceuticals reports second quarter 2017 financial results and provides business update.Corvus Pharmaceuticals Inc - qtrly ‍ net loss per share, basic and diluted $0.73​.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Corvus Pharmaceuticals announces interim results from its ongoing Phase 1/1b study
Monday, 5 Jun 2017 08:30am EDT 

June 5 (Reuters) - Corvus Pharmaceuticals Inc ::Announces interim results demonstrating anti-tumor activity of CPI-444 in renal and lung cancer patients resistant or refractory to prior PD-(L)1 treatment.Criteria met for second expansion of renal cell cancer cohort treated with combination therapy​.  Full Article

Corvus Pharmaceuticals and Monash University enter into exclusive license agreement
Tuesday, 9 May 2017 08:30am EDT 

May 9 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals and Monash University enter into exclusive license agreement for novel immuno-oncology program.Corvus Pharmaceuticals - licensed global rights to undisclosed novel immuno-oncology program, which includes lead product candidate, from Monash University.  Full Article

Corvus Pharma Q1 loss per share $0.79
Thursday, 4 May 2017 04:10pm EDT 

May 4 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals reports first quarter 2017 financial results and provides business update.Qtrly loss per share $0.79.  Full Article

Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Corvus Pharmaceuticals Inc : :Corvus Pharmaceuticals expands cpi-444 clinical collaboration with Genentech.Corvus Pharmaceuticals - Genentech will manage study operations for phase 1B/2 trial, which is expected to begin enrolling patients in second half of 2017.Corvus Pharmaceuticals Inc - financial terms were not disclosed.Corvus Pharmaceuticals Inc - Corvus will retain global development and commercialization rights to CPI-444.Corvus Pharmaceuticals Inc- expanded its clinical collaboration with Genentech, a member of Roche Group.Corvus Pharmaceuticals Inc- anticipated that randomized, controlled study will enroll up to 65 patients in treatment arm.  Full Article

Corvus Pharmaceuticals announces interim safety and efficacy results from its ongoing Phase 1/1B study of CPI-444
Tuesday, 4 Apr 2017 10:30am EDT 

Corvus Pharmaceuticals Inc : Corvus Pharmaceuticals announces interim results from ongoing Phase 1/1B study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers . Trial data showed that treatment with CPI-444 as a single agent and in combination with atezolizumab was well tolerated . Says CPI-444 has been well tolerated to date .Of 37 patients who showed evidence of disease control, 23 remain on treatment.  Full Article

BRIEF-Adams Street Partners Reports 15.5 Pct Stake In Corvus Pharma

* ADAMS STREET PARTNERS, LLC REPORTS 15.5 PERCENT STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 12, 2018 - SEC FILING‍​